This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 May 19;369(9574):1668-70.

doi: 10.1016/S0140-6736(07)60758-2.

Ovarian suppression for early breast cancer

Nicholas Wilcken¹, Martin Stockler

Affiliations

PMID: 17512837
DOI: 10.1016/S0140-6736(07)60758-2

Comment

Ovarian suppression for early breast cancer

Nicholas Wilcken et al. Lancet. 2007.

. 2007 May 19;369(9574):1668-70.

doi: 10.1016/S0140-6736(07)60758-2.

Authors

Nicholas Wilcken¹, Martin Stockler

Affiliation

¹ Department of Medical Oncology, Westmead and Nepean Hospitals and University of Sydney, NSW 2145, Australia. nicholas_wilcken@wmi.usyd.edu.au

PMID: 17512837
DOI: 10.1016/S0140-6736(07)60758-2

No abstract available

PubMed Disclaimer

Comment on

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
LHRH-agonists in Early Breast Cancer Overview group; Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. LHRH-agonists in Early Breast Cancer Overview group, et al. Lancet. 2007 May 19;369(9574):1711-23. doi: 10.1016/S0140-6736(07)60778-8. Lancet. 2007. PMID: 17512856

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information